Liprimar (Atorvastatin)

Atorvastatin inhibits the enzyme HMG‑CoA reductase, which is essential for cholesterol synthesis in the liver. By blocking this pathway, the drug reduces hepatic cholesterol production, leading to increased expression of LDL receptors and enhanced removal of LDL‑cholesterol from the bloodstream.

The appropriate dose of Liprimar is determined by a qualified prescriber based on the patient’s clinical condition, lipid profile, and response to therapy. Dosage may be adjusted over time to achieve target cholesterol levels while monitoring safety.

Liprimar is classified as Pregnancy Category X, meaning it is contraindicated during pregnancy because of potential fetal harm. It is also not recommended for breastfeeding mothers, as atorvastatin can be excreted in breast milk and may affect the infant.

To order Liprimar, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India supplies hospitals, pharmacies, and procurement teams worldwide, and will request verification of trade or institutional credentials before providing pricing, availability, shipping details, and any necessary import documentation.

Liprimar (atorvastatin) is a high‑potency statin with a long half‑life, offering robust LDL‑cholesterol reduction compared with lower‑intensity statins such as pravastatin. Its efficacy at lower doses and once‑daily dosing make it a common choice for patients needing substantial lipid lowering, though individual response and tolerance vary.

Liprimar tablets should be stored at ambient temperature, below 25 °C. Keep them in the original packaging to protect from moisture and light, and store out of reach of children.

Liprimar is taken orally, usually once daily, with or without food. The tablet should be swallowed whole with a glass of water. Patients should follow the dosing schedule prescribed by their healthcare professional.

Serious risks include rhabdomyolysis, a severe muscle breakdown that can lead to kidney failure, and significant liver injury indicated by elevated liver enzymes. Patients should report unexplained muscle pain, weakness, or dark urine promptly, and undergo regular liver function monitoring as advised.

Liprimar should not be used by individuals with active liver disease, unexplained persistent elevations of serum transaminases, or those who are pregnant or breastfeeding. It is also contraindicated in patients with known hypersensitivity to atorvastatin or any component of the formulation.